Minocycline Alone and in Combination with Polymyxin B, Meropenem, and Sulbactam against Carbapenem-Susceptible and -Resistant Acinetobacter baumannii in an In Vitro Pharmacodynamic Model
- 17 February 2021
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 65 (3)
Abstract
Acinetobacter baumannii is recognized as an urgent public health threat by the Centers for Disease Control and Prevention (CDC). Current treatment options are scarce, particularly against carbapenem-resistant Acinetobacter baumannii (CRAB). We simulated the impact of minocycline standard (200mg load+100mg Q12h) and high-dose (700mg load+ 350mg Q12h), polymyxin B (2.5mg/kg Q12h), sulbactam (1g Q6h and 9g/24h as continuous infusion) and meropenem (intermittent 1 or 2g Q8h and 6g/24h as continuous infusion) alone or in combination against CRAB and non-CRAB isolates by simulating human therapeutic dosing regimens in a 72-hour, in vitro pharmacodynamic model (IVPD). There were no monotherapy regimens that demonstrated bactericidal activity against the tested non-CRAB and CRAB. Resistance development was common in monotherapy regimens. Against the CRAB isolate, the triple combination of high-dose minocycline (fAUC/MIC 21.21), polymyxin B (fAUC/MIC 15.63), and continuous infusion sulbactam (67% T>MIC) was the most consistently active regimen. Against non-CRAB, the triple therapy regimen of high-dose minocycline (fAUC/MIC 84.84) with continuous infusion meropenem (100%T>MIC) and continuous infusion sulbactam (83%T>MIC), as well as the double therapy of high-dose minocycline (AUC/MIC 84.84) with continuous infusion meropenem (100%T>MIC) resulted persistently bactericidal activity. In conclusion, triple therapy with high dose minocycline, continuous infusion sulbactam, and polymyxin B produced the most significant kill against the carbapenem-resistant Acinetobacter baumannii, with no regrowth and minimal resistance development.Keywords
This publication has 33 references indexed in Scilit:
- Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistanceClinical Microbiology and Infection, 2012
- Evaluation of Ceftaroline Activity versus Daptomycin (DAP) against DAP-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Strains in an In Vitro Pharmacokinetic/Pharmacodynamic ModelAntimicrobial Agents and Chemotherapy, 2011
- Outbreak of Colistin-Resistant, Carbapenem-Resistant Klebsiella pneumoniae in Metropolitan Detroit, MichiganAntimicrobial Agents and Chemotherapy, 2011
- Minocycline to Improve Neurologic Outcome in Stroke (MINOS)Stroke, 2010
- Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distributionJournal of Antimicrobial Chemotherapy, 2009
- Pharmacodynamics of Minocycline against Staphylococcus aureus in an In Vitro Pharmacokinetic ModelAntimicrobial Agents and Chemotherapy, 2008
- Pharmacokinetics of Intravenous Polymyxin B in Critically Ill PatientsClinical Infectious Diseases, 2008
- Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients?Current Opinion in Critical Care, 2008
- Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumanniiAntimicrobial Agents and Chemotherapy, 2006
- Impact of Enterococcus faecalis on the Bactericidal Activities of Arbekacin, Daptomycin, Linezolid, and Tigecycline against Methicillin-Resistant Staphylococcus aureus in a Mixed-Pathogen Pharmacodynamic ModelAntimicrobial Agents and Chemotherapy, 2006